Qi Xin1, Miaomiao Yuan1,2, Wei Lv1, Huanping Li1, Xiaoxia Song1, Jun Lu1, Tao Jing3. 1. Institute of Pathogenic Biology, School of Basic Medical Sciences, Lanzhou University, Lanzhou, 730000, Gansu, People's Republic of China. 2. The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518000, Guangdong, People's Republic of China. 3. Institute of Pathogenic Biology, School of Basic Medical Sciences, Lanzhou University, Lanzhou, 730000, Gansu, People's Republic of China. jtao@lzu.edu.cn.
Abstract
BACKGROUND: Cystic echinococcosis (CE), caused by the larval stage of Echinococcus granulosus (sensu stricto), is a life-threatening but neglected zoonosis. Glycolytic enzymes are crucial molecules for the survival and development of E. granulosus. The aim of this study was to investigate the molecular characterization, immunogenicity, tissue distribution and serodiagnostic potential of E. granulosus hexokinase (EgHK), the first key enzyme in the glycolytic pathway. METHODS: EgHK was cloned and expressed in Escherichia coli. Specific serum antibodies were evaluated in mice immunized with recombinant EgHK (rEgHK). The location of EgHK in the larval stage of E. granulosus was determined using fluorescence immunohistochemistry, and the potential of rEgHK as a diagnostic antigen was investigated in patients with CE using indirect enzyme-linked immunosorbent assay (ELISA). RESULTS: Recombinant EgHK could be identified in the sera of patients with CE and in mouse anti-rEgHK sera. High titers of specific immunoglobulin G were induced in mice after immunization with rEgHK. EgHK was mainly located in the tegument, suckers and hooklets of protoscoleces and in the germinal layer and laminated layer of the cyst wall. The sensitivity and specificity of the rEgHK-ELISA reached 91.3% (42/46) and 87.8% (43/49), respectively. CONCLUSIONS: We have characterized the sequence, structure and location of EgHK and investigated the immunoreactivity, immunogenicity and serodiagnostic potential of rEgHK. Our results suggest that EgHK may be a promising candidate for the development of vaccines against E. granulosus and an effective antigen for the diagnosis of human CE.
BACKGROUND:Cystic echinococcosis (CE), caused by the larval stage of Echinococcus granulosus (sensu stricto), is a life-threatening but neglected zoonosis. Glycolytic enzymes are crucial molecules for the survival and development of E. granulosus. The aim of this study was to investigate the molecular characterization, immunogenicity, tissue distribution and serodiagnostic potential of E. granulosushexokinase (EgHK), the first key enzyme in the glycolytic pathway. METHODS: EgHK was cloned and expressed in Escherichia coli. Specific serum antibodies were evaluated in mice immunized with recombinant EgHK (rEgHK). The location of EgHK in the larval stage of E. granulosus was determined using fluorescence immunohistochemistry, and the potential of rEgHK as a diagnostic antigen was investigated in patients with CE using indirect enzyme-linked immunosorbent assay (ELISA). RESULTS: Recombinant EgHK could be identified in the sera of patients with CE and in mouse anti-rEgHK sera. High titers of specific immunoglobulin G were induced in mice after immunization with rEgHK. EgHK was mainly located in the tegument, suckers and hooklets of protoscoleces and in the germinal layer and laminated layer of the cyst wall. The sensitivity and specificity of the rEgHK-ELISA reached 91.3% (42/46) and 87.8% (43/49), respectively. CONCLUSIONS: We have characterized the sequence, structure and location of EgHK and investigated the immunoreactivity, immunogenicity and serodiagnostic potential of rEgHK. Our results suggest that EgHK may be a promising candidate for the development of vaccines against E. granulosus and an effective antigen for the diagnosis of human CE.
Authors: Erick T Tjhin; Henry M Staines; Donelly A van Schalkwyk; Sanjeev Krishna; Kevin J Saliba Journal: FEBS Lett Date: 2013-08-13 Impact factor: 4.124
Authors: Paul R Torgerson; Nilanthi R de Silva; Eric M Fèvre; Fumiko Kasuga; Mohammad B Rokni; Xiao-Nong Zhou; Banchob Sripa; Neyla Gargouri; Arve Lee Willingham; Claudia Stein Journal: Trends Parasitol Date: 2013-12-03
Authors: Mar Siles-Lucas; Carlos Sánchez-Ovejero; María González-Sánchez; Esperanza González; Juan Manuel Falcón-Pérez; Belgees Boufana; Federica Fratini; Adriano Casulli; Raúl Manzano-Román Journal: Vet Parasitol Date: 2017-01-23 Impact factor: 2.738
Authors: Raúl Manzano-Román; Carlos Sánchez-Ovejero; Ana Hernández-González; Adriano Casulli; Mar Siles-Lucas Journal: Biomed Res Int Date: 2015-10-04 Impact factor: 3.411